The 2002 Women's Health Initiative scared a generation of women off hormone therapy. Two decades later, the data has been re-analyzed, the formulations have changed, and the timing window matters more than the original report suggested. Here's where modern HRT actually sits on risk, who benefits most, and what to ask before any prescription.
What 2002 actually showed - and what got missed
WHI used oral conjugated equine estrogens (Premarin) plus medroxyprogesterone (Provera) in women averaging 63 years old, on average 12 years past menopause onset. The trial flagged increased breast cancer, stroke, and clot risk in that population.
Re-analysis: women started inside 10 years of menopause showed reduced all-cause mortality and cardiovascular benefit. Women over 60 starting fresh on systemic HRT carried more risk than benefit. Same molecule, very different outcome by timing.
The 2002 trial used oral estrogen, which raises clot risk through hepatic first-pass metabolism. Transdermal estradiol bypasses that pathway - clot risk in observational data tracks closer to baseline.
Modern formulations and the timing window
Standard of care now: transdermal estradiol (patch, gel, or spray) at 0.025-0.1 mg/day, combined with micronized progesterone (Prometrium) 100-200 mg nightly if the uterus is intact. Bioidentical molecules, lower clot signal, sleep benefit from progesterone.
The "window of opportunity" for cardiovascular and cognitive benefit appears strongest when started inside 10 years of menopause onset, ideally before age 60. Past that window, systemic HRT shifts toward neutral or net-risk for some endpoints.
Local vaginal estrogen (cream, ring, or tablet) is a separate conversation - low systemic absorption, used for genitourinary symptoms, safe even in many women who can't take systemic HRT.
Real risks, in real numbers
Breast cancer: combined estrogen + progestogen HRT raises risk by roughly 1 additional case per 1,000 women per year of use over baseline (~12 per 1,000 lifetime baseline becomes ~13). Estrogen-only HRT in women without a uterus: no clear increase, possibly protective.
Venous thromboembolism: oral HRT roughly doubles clot risk over baseline. Transdermal HRT shows little to no clot signal in the largest cohort studies. Personal or family history of DVT/PE shifts the math significantly.
Cardiovascular: started inside 10 years of menopause, transdermal HRT trends neutral to protective. Started over 60 or 10+ years post-menopause, the picture becomes mixed.
Who clears, who gets routed elsewhere
Strong candidates: women within 10 years of menopause onset with vasomotor symptoms, sleep disruption, mood changes, joint pain, or genitourinary symptoms. Bone density concerns also support the call.
Hard contraindications: history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, recent VTE, recent stroke, severe untreated hypertension. We will route to non-hormonal pathways instead.
Conditional cases: dense breast tissue, fibroids, prior fertility treatment exposure, family history of breast cancer - these aren't automatic disqualifications but require additional screening (mammogram, breast MRI in some cases) and a longer informed-consent conversation.
What to do now
If you're inside the 10-year window, symptomatic, and curious - run the Advanced lab panel and book the assessment. We screen breast, clot, liver, and cardiovascular history before any HRT prescription gets written.
If you have a history that complicates HRT, we'll route to non-hormonal options: gabapentin or fezolinetant for vasomotor symptoms, vaginal estrogen for GSM, SSRI/SNRI for mood, behavioral and lifestyle work for sleep. "No" on HRT isn't "no help."